Stories & News

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the...

Catch Up on LRA News with Lupus Research Update Vol. 1, 2022

February 17, 2022 It’s with great pride that I share a sampling of the many extraordinary accomplishments of last year...

Lupus Research Alliance Congratulates Dr. Robert Califf on FDA Commissioner Appointment

February 17, 2022 The Lupus Research Alliance applauds the appointment of Dr. Robert Califf as the Commissioner of the U.S....

Encouraging Results with Obinutuzumab for Lupus Nephritis

February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive...

LRA-Funded Research Aims at Preventing Heart Disease in Kids With Lupus

February 14, 2022 Being a kid isn't always easy, but growing up with lupus makes it a much harder challenge....

LRA-Funded Research Found a Connection Between the Epstein-Barr Virus Infection and MS as an Autoimmune Disease

February 4, 2022 A potential new cause of the autoimmune disease multiple sclerosis (MS) was discovered by researchers partly funded...

Baricitinib Development as a Lupus Treatment Discontinued

January 28, 2022 The Lupus Research Alliance is disappointed that the Phase 3 development program of OLUMIANT® (baricitinib) as a...

LRA-Funded Research Uncovers a Novel Pathway for Lupus Nephritis

January 28, 2022 The investigators from The Accelerated Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Program, in...

Shingles Vaccine Recommended for Immunocompromised People

January, 2022 As of January, 2022, the U.S. Centers for Disease Control and Prevention (CDC) recommends the use of the...

FDA Authorizes Evusheld Emergency Use to Prevent COVID-19 in Immunocompromised Patients

December 9, 2021 People with lupus can be immunocompromised because of the disease itself or medications that suppress the immune...

Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis

December 9, 2021 The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia...

LRA Partnering with NIH, FNIH and Others on Groundbreaking Initiative

December 9, 2021 The Lupus Research Alliance (LRA) is proud and excited to partner again with the National Institutes of...